New study data on the use of newer versus injectable disease modifying therapies (DMTs) in children with relapsing-remitting multiple sclerosis (RRMS) have led to calls for a shift in practice.
Dr Omar Abdel-Mannan from Great Ormond Street Hospital in London, UK, said the improved outcomes seen with the use of newer DMTs add to the evidence supporting their first-line use in pediatric MS.
Presenting at the ICNA/CNS 2020 virtual conference, Dr Abdel-Mannan reported findings from a real-world observational study involving 7 centers in the UK, and a total of 103 patients with a diagnosis of RRMS who were treated with DMTs between 2012 and 2018.